ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Drug Bills Cut $500 Million From Cancer Care, ASCO Says.

July 4, 2003

Proceedings Initiated Against Two Physicians At Dana-Farber

April 7, 1995

GAO Report: Taxol CRADA “Successful,” But Not Great Financial Deal.

June 27, 2003

USC Scientists Says It’s Time Nobelists Recognize Value of Cancer Program

February 10, 1978

NCI STRAP Grants Aim To Move Research Quickly To Clinical Trials

October 1, 2010

In Brief: Comis Named ECOG Chairman; Long Joins Capitol Associates; Chabner Day In Shelbyville

April 14, 1995